Bausch Health (BHC) Q4 2025 earnings review
Pipeline Blowout Overshadows Operational Beat
Bausch Health delivered its eleventh consecutive quarter of growth with Q4 revenue rising 9% to $2.80B, beating the trend of mid-single-digit gains. However, the narrative is heavily damaged by the Phase 3 failure of RED-C (Next-Gen Xifaxan), wiping out a key long-term growth pillar. While core Salix and Bausch + Lomb segments performed well, the Solta aesthetics business hit a sudden wall (-1% growth) due to China distribution changes, and a $145M goodwill impairment swung GAAP results to a $112M loss. 2026 guidance projects steady 2-5% growth, but the investment thesis now lacks its primary pipeline catalyst.
🐂 Bull Case
Despite age and maturity, the Salix segment (driven by Xifaxan) accelerated to 9% organic growth in Q4. The core cash engine remains intact and is growing faster than the 2025 full-year average.
The company generated $1.4B in operating cash flow for FY25 and successfully extended $1.6B in debt maturities to 2032. Financial discipline remains strong despite the GAAP loss.
🐻 Bear Case
The failure of the RED-C Phase 3 trials (prevention of hepatic encephalopathy) is a catastrophic blow to the long-term defense of the Xifaxan franchise. This removes the primary strategy for extending the lifecycle of the company's most important asset beyond 2028.
After quarters of blistering 20-30% growth, Solta Medical revenue suddenly reversed to -1% in Q4. While management blames one-time China distribution integration, such a sharp deceleration raises concerns about the durability of the aesthetics boom.
⚖️ Verdict: 🔴
Bearish. The operational beat is insufficient to offset the strategic damage from the RED-C clinical failure. With the main pipeline catalyst gone and Solta stalling, the growth story for 2026+ is significantly weaker.
Key Themes
RED-C Phase 3 Failure
In a major disclosure tucked into the release, BHC confirmed that its RED-C program (new formulation of rifaximin) failed to meet primary endpoints in Phase 3 trials. This asset was critical for managing the 'patent cliff' risk for Xifaxan. Its failure leaves the company more exposed to generic competition risks post-2028 without a clear successor product.
Solta Medical Sudden Reversal
Solta Medical has been the star performer, posting organic growth of 33%, 26%, and 24% in the first three quarters of 2025. In Q4, this collapsed to -1%. Management cites the acquisition of Shibo in China as a one-time impact, but the magnitude of the drop serves as a warning on the volatility of the aesthetics segment.
Salix Core Strength
Salix grew 9% organically in Q4, an acceleration from the full-year organic rate of 9%. Xifaxan remains the dominant driver. Despite looming patent/IRA threats, the commercial execution here remains flawless, providing the cash flow needed to service debt.
Generics Impairment & GAAP Losses
A $145M goodwill impairment in the Generics business pushed the company to a GAAP net loss of $112M for the quarter. While Adjusted EBITDA remains healthy, these recurring 'non-core' write-downs and adjustments continue to muddy the actual bottom-line profitability.
Bausch + Lomb Contribution
The Bausch + Lomb segment (which BHC still consolidates) grew 10% reported and 7% organically in Q4, driven by broad strength in Vision Care and Surgical. This segment continues to provide stability and scale, essentially anchoring the consolidated results.
R&D Pivot to Alcohol-Associated Hepatitis
With RED-C failing, pressure mounts on the newly acquired Larsucosterol (from DURECT). The Phase 3 trial initiated in Jan 2026. This is now the 'must-win' pipeline asset, elevating the execution risk profile for the next 12-24 months.
Other KPIs
Accelerating. Growth accelerated to +13% YoY in Q4, outpacing the +7% full-year growth rate. This indicates improved operating leverage and cost control closing out the year.
Decelerating. Down from $1.60B in FY24 (-12.5%). The drop is attributed to higher working capital and interest payments, a red flag for a company where deleveraging is the primary directive.
Accelerating. Surprised to the upside with +12% growth (9% organic), breaking a trend of decline/stagnation (FY25 organic growth was -3%). Driven significantly by the Generics unit, ironically the same unit that took the goodwill impairment.
Guidance
Decelerating. Implies 2-5% growth, a slowdown from the 7% reported growth delivered in FY25. Suggests management sees a reversion to mean after a strong 2025.
Decelerating. Implies 3-5% growth, compared to the 7% growth achieved in FY25. The guidance likely factors in the 'reset' in Solta and continued generic pressures.
Stable. The midpoint implies ~3% growth over FY25's $5.165B. This is conservative given the 6% organic growth posted in Q4, potentially hedging against further Solta volatility.
Decelerating. Forecast is lower than the $1.40B generated in FY25, suggesting continued headwinds from interest payments or working capital needs.
Key Questions
RED-C Failure Impact
With the primary endpoint missed for RED-C, what is the specific Plan B for the Xifaxan franchise post-2028? Does this force further M&A activity?
Solta China Integration
Can you quantify the 'one-time' impact of the Shibo acquisition on Q4 numbers? Specifically, when do you expect Solta to return to double-digit growth?
Generics Impairment
The Generics segment grew 167% in Q4, yet you took a $145M goodwill impairment on it. Can you reconcile this strong performance with the write-down?